Clinical trial
Vaccine Therapy in Treating Patients With Multiple Myeloma
NCT00019097 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019097 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Multiple Myeloma |
| Official title | Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim |
| Start date | Jul 1, 1995 |
| Completion | Mar 1, 2007 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: